½ÃÀ庸°í¼­
»óǰÄÚµå
1620807

¹æ»ç¼± Ä¡·á ½ÃÀå : Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Radiotherapy Market by Product (Hardware, Software & Service), Type (External Beam Radiotherapy/Teletherapy, Internal Beam Radiotherapy/Brachytherapy, Systemic Radiotherapy), Application, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¹æ»ç¼± Ä¡·á ½ÃÀåÀº 2023³â¿¡ 65¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 68¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.23%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 94¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹æ»ç¼± Ä¡·á´Â °í¿¡³ÊÁö ¹æ»ç¼±À» ÀÌ¿ëÇÏ¿© ¾Ï¼¼Æ÷ÀÇ DNA¸¦ ¼Õ»ó½Ã۰í Áõ½ÄÀ» ¾ïÁ¦ÇÔÀ¸·Î½á ¾Ï µîÀ» Ä¡·áÇÏ´Â ÀÇ·á ±â¼úÀÔ´Ï´Ù. ¹æ»ç¼± Ä¡·áÀÇ Çʿ伺Àº ÁÖº¯ °Ç°­ÇÑ Á¶Á÷À» º¸Á¸Çϸ鼭 ƯÁ¤ Á¾¾çÀ» Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ´Â È¿°ú·Î ÀÎÇØ Á¾¾çÇÐ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ ÇʼöÀûÀÎ ºÎºÐÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. ¹æ»ç¼± Ä¡·áÀÇ ¿ëµµ´Â Àü¸³¼±¾Ï, À¯¹æ¾Ï, Æó¾Ï, ³úÁ¾¾ç µî ´Ù¾çÇÑ ¾Ï Ä¡·á¿¡ Àû¿ëµË´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â ÁÖ·Î º´¿ø, ¾Ï Ä¡·á ¼¾ÅÍ ¹× ¿¬±¸ ±â°üÀÔ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¾Ï ¹ßº´·ü Áõ°¡, üºÎ Á¤À§ ¹æ»ç¼± Ä¡·á¿Í °°Àº ±â¼ú ¹ßÀü, ÀÇ·á ÀÎÇÁ¶ó¿¡ ÀÚ±ÝÀ» Áö¿øÇÏ´Â Á¤ºÎ Áö¿ø Á¤Ã¥ÀÔ´Ï´Ù. ¿µ»ó À¯µµ ¹× °­µµ º¯Á¶¿Í °°Àº ÃÖ±ÙÀÇ ±â¼ú Çõ½ÅÀº Á¤¹ÐÀÇ·á ¹× °³ÀÎ ¸ÂÃãÇü Ä¡·á ¿É¼Ç¿¡ ÅõÀÚÇÏ´Â ¾÷°è ÀÌÇØ°ü°èÀڵ鿡°Ô ÀáÀçÀûÀÎ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±×·¯³ª °í°¡ÀÇ Àåºñ ºñ¿ë°ú ¼÷·ÃµÈ ¿î¿µÀÚÀÇ Çʿ伺°ú °°Àº Á¦¾àÀÌ Á¸ÀçÇϸç, ƯÈ÷ ½ÅÈï±¹ ½ÃÀå¿¡¼­ ½ÃÀå °³Ã´À» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ºÎÀÛ¿ëÀÇ À§ÇèÀº ¶Ç ´Ù¸¥ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ÀΰøÁö´ÉÀ» ÅëÇÕÇÏ¿© Ä¡·áÀÇ Á¤È®¼º°ú ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â ¿¬±¸¿Í ±â¼ú Çõ½ÅÀº À¯¸ÁÇÑ ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°Ý ÀÇ·á ±â´ÉÀÇ È®´ë´Â »çÈÄ °ü¸® ¹× ¸ð´ÏÅ͸µ¿¡ Çõ¸íÀ» °¡Á®¿Ã ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀü¿¡µµ ºÒ±¸Çϰí, ½ÃÀå ÁøÃâ±â¾÷µéÀº ÁøÈ­ÇÏ´Â ±ÔÁ¦¿Í ´Ù¾çÇÑ »çȸ°æÁ¦Àû Áý´ÜÀÌ Æø³Ð°Ô Á¢±ÙÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀÇ Çʿ伺¿¡ ´ëÇÑ °æ°è¸¦ ´ÊÃßÁö ¾Ê¾Æ¾ß ÇÕ´Ï´Ù. Àü¹ÝÀûÀ¸·Î ¹æ»ç¼± Ä¡·á ½ÃÀåÀº ¿ªµ¿ÀûÀÎ ¼ºÀå ±Ëµµ¿¡ ÀÖÀ¸¸ç, Á¾ÇÕÀûÀÎ ¾Ï Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá ±â¼ú ¹ßÀü°ú Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¼ºÀåÇϰíÀÚ ÇÏ´Â Á¶Á÷Àº ½ÃÀå ±âȸ¸¦ ±Ø´ëÈ­Çϱâ À§ÇØ È¹±âÀûÀÎ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¿Í ¹ÌÃæÁ· Áö¿ª ¹× Àα¸ Áý´Ü¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë¶ó´Â µÎ °¡Áö Àü·«À» äÅÃÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 65¾ï 7,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 68¾ï 9,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 94¾ï ´Þ·¯
CAGR(%) 5.23%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ¹æ»ç¼± Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

¹æ»ç¼± Ä¡·á ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾Ï Ä¡·á¿¡¼­ ¹æ»ç¼± Ä¡·á ½Ã¼úÀÇ Ã¤Åà Ȯ´ë
    • Àúħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡
    • ¹æ»ç¼± Ä¡·á¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ÇÁ·Î±×·¥ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ³ôÀº Ä¡·á ºñ¿ë°ú ÈÆ·ÃµÈ Àü¹®°¡ ºÎÁ·
  • ½ÃÀå ±âȸ
    • ¼Ò¾Æ¾Ï Ä¡·á¸¦ À§ÇÑ Ã·´Ü ¹æ»ç¼± Ä¡·á Àåºñ °³¹ß
    • ¾Ï Ä¡·á¿ë ·Îº¿ ¹æ»ç¼± Ä¡·á ½Ã½ºÅÛ ¼Ò°³
  • ½ÃÀå °úÁ¦
    • ¹æ»ç¼± ÇÇÆø¿¡ µû¸¥ À§Ç輺

Porter's Five Forces: ¹æ»ç¼± Ä¡·á ½ÃÀå Ž»öÀ» À§ÇÑ Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. PorterÀÇ Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ¹æ»ç¼± Ä¡·á ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ¹æ»ç¼± Ä¡·á ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ¹æ»ç¼± Ä¡·á ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

¹æ»ç¼± Ä¡·á ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¹æ»ç¼± Ä¡·á ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ¹æ»ç¼± Ä¡·á ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¹æ»ç¼± Ä¡·á ½ÃÀå¿¡¼­ÀÇ ¼º°ø Àü·« ºÐ¼® ¹× Ãßõ ¹æ»ç¼± Ä¡·á ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ ±×¸³´Ï´Ù.

¹æ»ç¼± Ä¡·á ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
    • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
      • Á¤Ä¡Àû
      • °æÁ¦Àû
      • »çȸÀû
      • ±â¼úÀû
      • ¹ýÀû
      • ȯ°æÀû

    Á¦6Àå ¹æ»ç¼± Ä¡·á ½ÃÀå : Á¦Ç°º°

    • Çϵå¿þ¾î
    • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

    Á¦7Àå ¹æ»ç¼± Ä¡·á ½ÃÀå : À¯Çüº°

    • ¿ÜºÎ ¹æ»ç¼±Ä¡·á/¿ø°ÝÄ¡·á
      • ±âÁ¸ Cabalt-60 ¿ø°Ý Ä¡·á À¯´Ö
      • ¼±Çü °¡¼Ó±â
        • Á¾·¡ÀÇ ¼±Çü °¡¼Ó±â
        • »çÀ̹ö ³ªÀÌÇÁ Åä¸ð Å×¶óÇÇ
        • °¨¸¶³ªÀÌÇÁ
        • MRI ¸®´Ï¾î
        • Á¤À§Àû ¼±Áø ÀüÀÚ/ÄÚ¹ßÆ® 60 ¼±Çü °¡¼Ó±â
      • ÀÔÀÚ¼± Ä¡·á ½Ã½ºÅÛ
        • »çÀÌŬ·ÎÆ®·Ð
        • ½ÌÅ©·Î»çÀÌŬ·ÎÆ®·Ð
        • ½ÌÅ©·ÎÆ®·Ð
    • ³»ºÎ Á¶»ç ¹æ»ç¼± Ä¡·á/±ÙÁ¢ ¹æ»ç¼± Ä¡·á
      • ¾ÖÇÁÅÍ ·Î´õ
      • ¾îÇø®ÄÉÀÌÅÍ
      • IORT ½Ã½ºÅÛ
      • ¾¾¾Ñ
    • ü°èÀûÀÎ ¹æ»ç¼± Ä¡·á
      • ·Îº¥±¸¾Æ³×(l-131)
      • ·¹´½ 186
      • »ç¸¶·ý 153

    Á¦8Àå ¹æ»ç¼± Ä¡·á ½ÃÀå : ¿ëµµº°

    • À¯¹æ¾Ï
    • ÀڱðæºÎ¾Ï
    • ´ëÀå¾Ï
    • µÎ°æºÎ¾Ï
    • Æó¾Ï
    • Àü¸³¼±¾Ï

    Á¦9Àå ¹æ»ç¼± Ä¡·á ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

    • º´¿ø
    • µ¶¸³ ¹æ»ç¼± Ä¡·á ¼¾ÅÍ
    • ¿¬±¸±â°ü

    Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ¹æ»ç¼± Ä¡·á ½ÃÀå

    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹

    Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹æ»ç¼± Ä¡·á ½ÃÀå

    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • Àεµ³×½Ã¾Æ
    • ÀϺ»
    • ¸»·¹À̽þÆ
    • Çʸ®ÇÉ
    • ½Ì°¡Æ÷¸£
    • Çѱ¹
    • ´ë¸¸
    • ű¹
    • º£Æ®³²

    Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹æ»ç¼± Ä¡·á ½ÃÀå

    • µ§¸¶Å©
    • ÀÌÁýÆ®
    • Çɶõµå
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • À̽º¶ó¿¤
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ³ªÀÌÁö¸®¾Æ
    • ³ë¸£¿þÀÌ
    • Æú¶õµå
    • īŸ¸£
    • ·¯½Ã¾Æ
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ½ºÀ§½º
    • ÅÍŰ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ¿µ±¹

    Á¦13Àå °æÀï ±¸µµ

    • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
    • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
    • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Àü·« ºÐ¼®°ú Á¦¾È
      • Áö¸à½º AG

    ±â¾÷ ¸ñ·Ï

    • Accuray Incorporated
    • Agilent Technologies Inc.
    • Becton, Dickinson and Company
    • Cardinal Health, Inc.
    • Charles River Laboratories International, Inc.
    • Elekta AB
    • F. Hoffmann-La Roche Ltd.
    • GE HealthCare Technologies Inc.
    • IBA Dosimetry GmbH
    • IntraOp Medical, Inc.
    • Koninklijke Philips NV
    • Leo Cancer Care
    • Mevion Medical Systems
    • Panacea Medical Technologies Pvt. Ltd.
    • PerkinElmer, Inc.
    • Qfix
    • Quanterix Corporation
    • Radiology Oncology Systems
    • Siemens AG
    • ZEISS Group
    BJH 25.01.08

    The Radiotherapy Market was valued at USD 6.57 billion in 2023, expected to reach USD 6.89 billion in 2024, and is projected to grow at a CAGR of 5.23%, to USD 9.40 billion by 2030.

    Radiotherapy is a medical technique that utilizes high-energy radiation to treat cancer and other conditions by damaging the DNA of cancerous cells, thereby inhibiting their growth. Its necessity arises from its effectiveness in targeting specific tumors while sparing surrounding healthy tissue, making it an integral part of oncology treatment protocols. Applications of radiotherapy extend to treating various types of cancers, including prostate, breast, lung, and brain tumors. End-use scope primarily encompasses hospitals, cancer treatment centers, and research institutions. Market growth is driven by the increasing prevalence of cancer, advancements in technology like stereotactic body radiation therapy, and supportive government policies financing healthcare infrastructure. Recent innovations such as Image-guided and intensity-modulated radiotherapy offer potential opportunities for industry stakeholders to invest in precision medicine and personalized treatment options. However, certain limitations exist, including high equipment costs and a need for skilled operators, which may constrain market expansion, particularly in developing regions. Moreover, stringent regulatory frameworks and the risk of side effects present additional challenges. There is a promising avenue for research and innovation in integrating artificial intelligence to enhance treatment precision and patient outcomes. Additionally, expanding telemedicine capabilities might revolutionize aftercare and monitoring. Despite these advances, market participants must remain vigilant about evolving regulations and the need for cost-effective solutions to ensure broad access across different socio-economic populations. Overall, the radiotherapy market exhibits a dynamic growth trajectory with significant potential hinging on technological advancements and strategic alliances focused on comprehensive cancer care. Organizations aiming for growth should adopt a dual strategy of groundbreaking technology investments and broadening access in underrepresented regions and populations to maximize market opportunities.

    KEY MARKET STATISTICS
    Base Year [2023] USD 6.57 billion
    Estimated Year [2024] USD 6.89 billion
    Forecast Year [2030] USD 9.40 billion
    CAGR (%) 5.23%

    Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Radiotherapy Market

    The Radiotherapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

    • Market Drivers
      • Growing adoption of radiotherapy procedures for cancer treatment
      • Rising preference for minimally invasive procedures
      • Increasing government initiatives and programs for radiotherapy
    • Market Restraints
      • High treatment costs and limited availability of trained professionals
    • Market Opportunities
      • Development of advanced radiotherapy equipment for pediatric oncology
      • Introduction of robotic radiotherapy systems for cancer treatment
    • Market Challenges
      • Risks associated with radiation exposure

    Porter's Five Forces: A Strategic Tool for Navigating the Radiotherapy Market

    Porter's five forces framework is a critical tool for understanding the competitive landscape of the Radiotherapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

    PESTLE Analysis: Navigating External Influences in the Radiotherapy Market

    External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Radiotherapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

    Market Share Analysis: Understanding the Competitive Landscape in the Radiotherapy Market

    A detailed market share analysis in the Radiotherapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

    FPNV Positioning Matrix: Evaluating Vendors' Performance in the Radiotherapy Market

    The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Radiotherapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

    Strategy Analysis & Recommendation: Charting a Path to Success in the Radiotherapy Market

    A strategic analysis of the Radiotherapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

    Key Company Profiles

    The report delves into recent significant developments in the Radiotherapy Market, highlighting leading vendors and their innovative profiles. These include Accuray Incorporated, Agilent Technologies Inc., Becton, Dickinson and Company, Cardinal Health, Inc., Charles River Laboratories International, Inc., Elekta AB, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., IBA Dosimetry GmbH, IntraOp Medical, Inc., Koninklijke Philips N.V., Leo Cancer Care, Mevion Medical Systems, Panacea Medical Technologies Pvt. Ltd., PerkinElmer, Inc., Qfix, Quanterix Corporation, Radiology Oncology Systems, Siemens AG, and ZEISS Group.

    Market Segmentation & Coverage

    This research report categorizes the Radiotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

    • Based on Product, market is studied across Hardware and Software & Service.
    • Based on Type, market is studied across External Beam Radiotherapy/Teletherapy, Internal Beam Radiotherapy/Brachytherapy, and Systemic Radiotherapy. The External Beam Radiotherapy/Teletherapy is further studied across Conventional Cabalt-60 Teletherapy Units, Linear Accelerators, and Particle Therapy Systems. The Linear Accelerators is further studied across Conventional Linear Accelerators, CyberKnife TomoTherapy, Gamma Knife, MRI LINAC, and Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators. The Particle Therapy Systems is further studied across Cyclotrons, Synchrocyclotron, and Synchrotrons. The Internal Beam Radiotherapy/Brachytherapy is further studied across Afterloaders, Applicators, IORT Systems, and Seeds. The Systemic Radiotherapy is further studied across lobenguane (l-131), Rhenium-186, and Samarium-153.
    • Based on Application, market is studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Head & Neck Cancer, Lung Cancer, and Prostate Cancer.
    • Based on End-User, market is studied across Hospitals, Independent Radiotherapy Centers, and Research Organizations.
    • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

    The report offers a comprehensive analysis of the market, covering key focus areas:

    1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

    2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

    3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

    4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

    5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

    The report also answers critical questions to aid stakeholders in making informed decisions:

    1. What is the current market size, and what is the forecasted growth?

    2. Which products, segments, and regions offer the best investment opportunities?

    3. What are the key technology trends and regulatory influences shaping the market?

    4. How do leading vendors rank in terms of market share and competitive positioning?

    5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

    Table of Contents

    1. Preface

    • 1.1. Objectives of the Study
    • 1.2. Market Segmentation & Coverage
    • 1.3. Years Considered for the Study
    • 1.4. Currency & Pricing
    • 1.5. Language
    • 1.6. Stakeholders

    2. Research Methodology

    • 2.1. Define: Research Objective
    • 2.2. Determine: Research Design
    • 2.3. Prepare: Research Instrument
    • 2.4. Collect: Data Source
    • 2.5. Analyze: Data Interpretation
    • 2.6. Formulate: Data Verification
    • 2.7. Publish: Research Report
    • 2.8. Repeat: Report Update

    3. Executive Summary

    4. Market Overview

    5. Market Insights

    • 5.1. Market Dynamics
      • 5.1.1. Drivers
        • 5.1.1.1. Growing adoption of radiotherapy procedures for cancer treatment
        • 5.1.1.2. Rising preference for minimally invasive procedures
        • 5.1.1.3. Increasing government initiatives and programs for radiotherapy
      • 5.1.2. Restraints
        • 5.1.2.1. High treatment costs and limited availability of trained professionals
      • 5.1.3. Opportunities
        • 5.1.3.1. Development of advanced radiotherapy equipment for pediatric oncology
        • 5.1.3.2. Introduction of robotic radiotherapy systems for cancer treatment
      • 5.1.4. Challenges
        • 5.1.4.1. Risks associated with radiation exposure
    • 5.2. Market Segmentation Analysis
      • 5.2.1. Product: Advancements in hardware manufacturing process as it provide high radiation doses to the tumor site
      • 5.2.2. Type: Consumer preference for external beam radiotherapy/teletherapy as they target tumor from outside and large tumors
      • 5.2.3. Procedure: Increasing advancements in external beam radiotherapy to streamline process and improve patient comfort
      • 5.2.4. Application: Growing application of radiotherapy for gynecological cancer
      • 5.2.5. End-User: Significant role of radiotherapy for hospitals service as they provide comprehensive care for cancer patients
    • 5.3. Porter's Five Forces Analysis
      • 5.3.1. Threat of New Entrants
      • 5.3.2. Threat of Substitutes
      • 5.3.3. Bargaining Power of Customers
      • 5.3.4. Bargaining Power of Suppliers
      • 5.3.5. Industry Rivalry
    • 5.4. PESTLE Analysis
      • 5.4.1. Political
      • 5.4.2. Economic
      • 5.4.3. Social
      • 5.4.4. Technological
      • 5.4.5. Legal
      • 5.4.6. Environmental

    6. Radiotherapy Market, by Product

    • 6.1. Introduction
    • 6.2. Hardware
    • 6.3. Software & Service

    7. Radiotherapy Market, by Type

    • 7.1. Introduction
    • 7.2. External Beam Radiotherapy/Teletherapy
      • 7.2.1. Conventional Cabalt-60 Teletherapy Units
      • 7.2.2. Linear Accelerators
        • 7.2.2.1. Conventional Linear Accelerators
        • 7.2.2.2. CyberKnife TomoTherapy
        • 7.2.2.3. Gamma Knife
        • 7.2.2.4. MRI LINAC
        • 7.2.2.5. Stereotactic Advanced Electron/Cobalt-60 Linear Accelerators
      • 7.2.3. Particle Therapy Systems
        • 7.2.3.1. Cyclotrons
        • 7.2.3.2. Synchrocyclotron
        • 7.2.3.3. Synchrotrons
    • 7.3. Internal Beam Radiotherapy/Brachytherapy
      • 7.3.1. Afterloaders
      • 7.3.2. Applicators
      • 7.3.3. IORT Systems
      • 7.3.4. Seeds
    • 7.4. Systemic Radiotherapy
      • 7.4.1. lobenguane (l-131)
      • 7.4.2. Rhenium-186
      • 7.4.3. Samarium-153

    8. Radiotherapy Market, by Application

    • 8.1. Introduction
    • 8.2. Breast Cancer
    • 8.3. Cervical Cancer
    • 8.4. Colorectal Cancer
    • 8.5. Head & Neck Cancer
    • 8.6. Lung Cancer
    • 8.7. Prostate Cancer

    9. Radiotherapy Market, by End-User

    • 9.1. Introduction
    • 9.2. Hospitals
    • 9.3. Independent Radiotherapy Centers
    • 9.4. Research Organizations

    10. Americas Radiotherapy Market

    • 10.1. Introduction
    • 10.2. Argentina
    • 10.3. Brazil
    • 10.4. Canada
    • 10.5. Mexico
    • 10.6. United States

    11. Asia-Pacific Radiotherapy Market

    • 11.1. Introduction
    • 11.2. Australia
    • 11.3. China
    • 11.4. India
    • 11.5. Indonesia
    • 11.6. Japan
    • 11.7. Malaysia
    • 11.8. Philippines
    • 11.9. Singapore
    • 11.10. South Korea
    • 11.11. Taiwan
    • 11.12. Thailand
    • 11.13. Vietnam

    12. Europe, Middle East & Africa Radiotherapy Market

    • 12.1. Introduction
    • 12.2. Denmark
    • 12.3. Egypt
    • 12.4. Finland
    • 12.5. France
    • 12.6. Germany
    • 12.7. Israel
    • 12.8. Italy
    • 12.9. Netherlands
    • 12.10. Nigeria
    • 12.11. Norway
    • 12.12. Poland
    • 12.13. Qatar
    • 12.14. Russia
    • 12.15. Saudi Arabia
    • 12.16. South Africa
    • 12.17. Spain
    • 12.18. Sweden
    • 12.19. Switzerland
    • 12.20. Turkey
    • 12.21. United Arab Emirates
    • 12.22. United Kingdom

    13. Competitive Landscape

    • 13.1. Market Share Analysis, 2023
    • 13.2. FPNV Positioning Matrix, 2023
    • 13.3. Competitive Scenario Analysis
      • 13.3.1. GlyTherix and SHINE Technologies partner to enhance targeted radiotherapy treatments for aggressive cancers using Lu-177
      • 13.3.2. GE Healthcare and Elekta's strategic alliance aims to enhance radiation therapy with advanced AI integration
      • 13.3.3. Bristol Myers Squibb strengthens oncology pipeline with RayzeBio acquisition
      • 13.3.4. CIVCO Radiotherapy and Qfix Launch CQ Medical Brand
      • 13.3.5. GE HealthCare Collaborates with Elekta to Expand Access to Precision Radiation Therapy Solutions in India
      • 13.3.6. IBA Launches Latest Radiation Therapy Quality Assurance Offerings
    • 13.4. Strategy Analysis & Recommendation
      • 13.4.1. Siemens AG

    Companies Mentioned

    • 1. Accuray Incorporated
    • 2. Agilent Technologies Inc.
    • 3. Becton, Dickinson and Company
    • 4. Cardinal Health, Inc.
    • 5. Charles River Laboratories International, Inc.
    • 6. Elekta AB
    • 7. F. Hoffmann-La Roche Ltd.
    • 8. GE HealthCare Technologies Inc.
    • 9. IBA Dosimetry GmbH
    • 10. IntraOp Medical, Inc.
    • 11. Koninklijke Philips N.V.
    • 12. Leo Cancer Care
    • 13. Mevion Medical Systems
    • 14. Panacea Medical Technologies Pvt. Ltd.
    • 15. PerkinElmer, Inc.
    • 16. Qfix
    • 17. Quanterix Corporation
    • 18. Radiology Oncology Systems
    • 19. Siemens AG
    • 20. ZEISS Group
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦